Boston Scientific plans changes to expected $200M tariff hit as situation shifts
The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.
The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.
